Methods for Estimating Long-Term Outcomes for Trastuzumab Deruxtecan in HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies

BACKGROUND: DESTINY-Breast01 (NCT03248492) is a phase II single-arm trial evaluating trastuzumab deruxtecan (T-DXd) in adults with human epidermal growth factor receptor 2-positive (HER2+) unresectable or metastatic breast cancer (u/mBC) who have received two or more prior anti-HER2 therapies. OBJEC...

Descripción completa

Detalles Bibliográficos
Autores principales: Dunton, Kyle, Vondeling, Gerard, Hancock, Elizabeth, Petrou, Margaret, Burn, Oliver, Paine, Abby
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684219/
https://www.ncbi.nlm.nih.gov/pubmed/36342619
http://dx.doi.org/10.1007/s11523-022-00923-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684219/
https://www.ncbi.nlm.nih.gov/pubmed/36342619
http://dx.doi.org/10.1007/s11523-022-00923-9

Ejemplares similares